Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Home
Publications
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Authors:
GH
Glenn J. Hanna
Glenn J. Hanna
LO
L. B. Oakley
L. B. Oakley
RS
R. Shi
R. Shi
AO
A. Oneill
A. Oneill
KS
K. Y. Shin
K. Y. Shin
NS
N. Scarfo
N. Scarfo
KS
K. Sehgal
K. Sehgal
MD
M. J. Dennis
M. J. Dennis
NQ
N. Quinn
N. Quinn
VJ
V. Y. Jo
V. Y. Jo
KW
K. Wong
K. Wong
AS
A. Shvyrkova
A. Shvyrkova
See more
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Open Access
Publisher website
Google Scholar
17 February 2025
other
Published by
American Association for Cancer Research (AACR)
DOI:
10.1158/1078-0432.28428205
Abstract
Supplemental Table 2. Representativeness of Study Participants.
Keywords
CLINICAL TRIAL RESULTS
PHASE II CLINICAL TRIALS
HEAD, NECK & ORAL CANCERS
PRECISION MEDICINE
TRANSLATIONAL RESEARCH
Related articles
Scroll to top